Home › Upcoming votes › Neuphoria Therapeutics Inc.
This meeting took place on November 2, 2026. Official results not yet filed. Companies report them on Form 8-K, usually within four business days of the meeting; they will appear here once they have been read.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Neuphoria Therapeutics Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 2 sets of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTOR Director election |
Board | For | 4 nominees; support 15% to 83% |
| 2 | RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Auditor |
Board | For | — |
| 3 | AUTHORIZATION OF ADJOURNMENT OF THE ANNUAL MEETING Adjournment |
Board | For | — |
From Neuphoria Therapeutics Inc.’s Form 8-K, filed December 17, 2025, for the meeting held December 12, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Peter Miles Davies | 83% | — |
| Elect Director: David Wilson | 83% | — |
| Elect Director: Stephen Doberstein | 15% | — |
| Elect Director: Kimberly Smith | 15% | — |
| Proposal 2: as follows: | 89% | — |
| Proposal 3: as follows: | 82% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.